142 related articles for article (PubMed ID: 31149211)
1. BODY MASS INDEX AS A PROGNOSTIC FACTOR FOR DISEASE PROGRESSION IN PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH BEVACIZUMAB BASED SYSTEMIC THERAPY.
Hopirtean C; Ciuleanu T; Cainap C; Todor N; Nagy V
Acta Endocrinol (Buchar); 2017; 13(4):425-430. PubMed ID: 31149211
[TBL] [Abstract][Full Text] [Related]
2. Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy.
Cybulska-Stopa B; Ługowska I; Wiśniowski R; Domagała-Haduch M; Rajczykowski M; Piejko K; Bar-Letkiewicz I; Suwiński R; Regulski K; Mackiewicz J
Contemp Oncol (Pozn); 2020; 24(1):34-41. PubMed ID: 32514236
[TBL] [Abstract][Full Text] [Related]
3. Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy.
Faruk Aykan N; Yildiz I; Sen F; Kilic L; Keskin S; Ciftci R; Karabulut S; Sakar B; Disci R
Med Oncol; 2013; 30(3):679. PubMed ID: 23921648
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy with TAS-102 plus bevacizumab in salvage-line treatment of metastatic colorectal cancer: A single-center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage-line therapy of metastatic colorectal cancer.
Matsuhashi N; Takahashi T; Fujii H; Suetsugu T; Fukada M; Iwata Y; Tokumaru Y; Imai T; Mori R; Tanahashi T; Matsui S; Imai H; Tanaka Y; Yamaguchi K; Futamura M; Yoshida K
Mol Clin Oncol; 2019 Oct; 11(4):390-396. PubMed ID: 31475067
[TBL] [Abstract][Full Text] [Related]
5. Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients.
Artaç M; Korkmaz L; Coşkun HŞ; Dane F; Karabulut B; Karaağaç M; Çabuk D; Karabulut S; Aykan NF; Doruk H; Avcı N; Turhal NS
J Gastrointest Cancer; 2019 Jun; 50(2):214-220. PubMed ID: 29302856
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
[TBL] [Abstract][Full Text] [Related]
7. Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer-the Experience of a Tertiary Cancer Center.
Căinap C; Bochiş OV; Vlad C; Popita R; Achimaş-Cadariu P; Havasi A; Vidrean A; Dranca A; Piciu A; Constantin AM; Tat T; Dana M; Crişan O; Cioban CV; Bălăcescu O; Coza O; Bălăcescu L; Marta MM; Bota M; Căinap S
Front Pharmacol; 2021; 12():487316. PubMed ID: 33776758
[No Abstract] [Full Text] [Related]
8. The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).
Bendell JC; Sauri T; Gracián AC; Alvarez R; López-López C; García-Alfonso P; Hussein M; Miron ML; Cervantes A; Montagut C; Vivas CS; Bessudo A; Plezia P; Moons V; Andel J; Bennouna J; van der Westhuizen A; Samuel L; Rossomanno S; Boetsch C; Lahr A; Franjkovic I; Heil F; Lechner K; Krieter O; Hurwitz H;
Oncologist; 2020 Mar; 25(3):e451-e459. PubMed ID: 32162804
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO.
Dell'Aquila E; Rossini D; Galletti A; Stellato M; Boccaccino A; Conca V; Germani MM; Bergamo F; Daniel F; Spagnoletti A; Provenzano L; Tomasello G; Zaniboni A; Buonadonna A; Fanchini L; Cupini S; Carlomagno C; Caponnetto S; Rapisardi S; Santini D
Clin Colorectal Cancer; 2022 Sep; 21(3):220-228. PubMed ID: 35304089
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.
Bruera G; Cannita K; Di Giacomo D; Lamy A; Troncone G; Dal Mas A; Coletti G; Frébourg T; Sabourin JC; Tosi M; Ficorella C; Ricevuto E
BMC Med; 2012 Nov; 10():135. PubMed ID: 23136868
[TBL] [Abstract][Full Text] [Related]
12. Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC).
El-Deiry WS; Winer A; Slifker M; Taylor S; Adamson BJS; Meropol NJ; Ross EA
Front Oncol; 2019; 9():142. PubMed ID: 30923702
[No Abstract] [Full Text] [Related]
13. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M
Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers for the early detection of relapses in metastatic colorectal cancers.
Chereches G; Barbos O; Buiga R; Balacescu O; Iancu D; Todor N; Balacescu L; Miron N; Bejinariu N; Ciuleanu TE
J BUON; 2017; 22(3):658-666. PubMed ID: 28730771
[TBL] [Abstract][Full Text] [Related]
15. A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for
He J; Liu Y; Liu C; Hu H; Sun L; Xu D; Li J; Wang J; Chen X; Lin R; Jiang Y; Zhang Y; Zhang W; Cheng Y; Wu X; Fang M; Li E; Xu Y; Chen Y; Li J; Cui Y; Pan Z; Zhang S; Yuan Y; Ding K
Technol Cancer Res Treat; 2023; 22():15330338231152350. PubMed ID: 36727222
[No Abstract] [Full Text] [Related]
16. Retrospective Comparative Analysis of KRAS G12C
Giampieri R; Lupi A; Ziranu P; Bittoni A; Pretta A; Pecci F; Persano M; Giglio E; Copparoni C; Crocetti S; Mandolesi A; Faa G; Coni P; Scartozzi M; Berardi R
Front Oncol; 2021; 11():736104. PubMed ID: 34660299
[TBL] [Abstract][Full Text] [Related]
17. The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study.
Hammerman A; Greenberg-Dotan S; Battat E; Feldhamer I; Bitterman H; Brenner B
Acta Oncol; 2015 Feb; 54(2):164-70. PubMed ID: 25350524
[TBL] [Abstract][Full Text] [Related]
18. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.
Bruera G; Cannita K; Giuliante F; Lanfiuti Baldi P; Vicentini R; Marchetti P; Nuzzo G; Antonucci A; Ficorella C; Ricevuto E
Clin Colorectal Cancer; 2012 Jun; 11(2):119-26. PubMed ID: 22206922
[TBL] [Abstract][Full Text] [Related]
20. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
